LY2109761

Overview

LY2109761 is an orally active, selective TGF-β receptor type I/II inhibitor with K i s of 38 nM and 300 nM, respectively.

Application

Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Obesity | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > TGF-β Receptor | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-12075
• CAS No.: 700874-71-1
• Molecular Formula: C26H27N5O2
• Molecular Weight: 441.52
• Purity: 99.72%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: 1 mg/mL (2.26 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source